云南白药出手！拟6.6亿元收购聚药堂100%股权

Core Viewpoint - Yunnan Baiyao announced the acquisition of 100% equity in An Guo Shi Ju Yao Tang Pharmaceutical Co., Ltd. for a total consideration of 660 million yuan to enhance its national business layout and scale expansion [2][6]. Group 1: Acquisition Details - The acquisition is aimed at boosting the sales of traditional Chinese medicine materials within Yunnan Province and expanding Yunnan Baiyao's business nationwide [2][7]. - An Guo Shi Ju Yao Tang specializes in the production and sales of traditional Chinese medicine pieces and formula granules, boasting a comprehensive product range with 1,567 types of medicinal pieces and 240 registered formula granules [5][6]. - The target company has a strong production capacity, with an annual output of 25,000 tons for medicinal pieces and 1,500 tons for formula granules, ranking among the top in the industry [5]. Group 2: Financial Performance and Commitments - An Guo Shi Ju Yao Tang reported a net profit of 69.33 million yuan for 2024 and 11.49 million yuan for the first quarter of this year [6]. - The acquisition includes performance commitments, with projected revenues of 624 million yuan, 616 million yuan, and 666 million yuan for 2025 to 2027, and net profits of 66 million yuan, 59.7 million yuan, and 63.9 million yuan respectively [6]. Group 3: Strategic Implications - The acquisition aligns with Yunnan Baiyao's strategy to expand its market presence outside of Yunnan and enhance its product offerings, thereby increasing competitiveness in the industry [9]. - The integration of An Guo Shi Ju Yao Tang's established online sales channels and extensive B2B customer base is expected to significantly improve the efficiency of Yunnan Baiyao's traditional Chinese medicine supply chain [9]. - Yunnan Baiyao's first-quarter report for 2025 indicated a revenue of 10.841 billion yuan, a year-on-year increase of 0.62%, and a net profit of 1.935 billion yuan, reflecting a growth of 13.67% [9].